| | Today's Big News Sep 16, 2022 AbbVie and Bristol Myers Squibb are laying off a total of 360 staffers on the West Coast: BMS is slimming down its workforce by 99 across two separate sites in San Diego County, while 261 employees will be let go from an AbbVie facility in Irvine, CA. Anywhere from 53% to 68% of US hospitals will end 2022 with operations in the red versus the 34% reported in 2019, according to new industry projections released by Kaufman Hall on behalf of the American Hospital Association. After uncovering several patient safety and cybersecurity risks in many of its infusion pumps, Baxter is now recalling another product that works alongside those pumps, known as IV sets. As of this week, the FDA has categorized the recall as Class I, indicating high risk of patient injury or death. - Gabrielle Masson | Lumanity’s research scientists and data luminaries can identify fit-for-purpose RWD and design studies to generate the strongest evidence to meet stakeholder needs. Learn more. 
|
| By Fraiser Kansteiner In separate Worker Adjustment and Retraining Notification (WARN) alerts filed this week, AbbVie and BMS let California know they plan to lay off 99 and 261 employees, respectively, by the end of November. For BMS, some of the layoffs are tied to a recent acquisition. |
|
|
By Dave Muoio A new report warns that anywhere from 53% to 68% of the nation's hospitals will finish 2022 with red operating margins. For systems large and small, this means service line closures or outright shutdowns that threaten patients' access to care, hospital leaders warned Thursday. By Andrea Park After uncovering a handful of patient safety and cybersecurity risks in many of its infusion pumps over the last year, Baxter has now begun a recall of yet another product that works alongside those pumps. By James Waldron AstraZeneca’s $39 billion acquisition of Alexion last year continues to look like money well spent. The latest good news is that the oral factor D inhibitor danicopan can improve hemoglobin levels when added to the approved drugs Ultomiris or Soliris. By Fraiser Kansteiner Friday, the European Medicines Agency’s human medicines committee, CHMP, vouched for approval of Beyfortus. The drug is in the running to prevent RSV lower respiratory tract disease in newborns and infants during their first RSV season and—if approved—would become the first single-dose passive immunization for the broad infant population. By James Waldron Intellia Therapeutics is closing out the week strong, reporting good news for a duo of gene editing trials. Both are early-stage, but the company is already prepping to move the transthyretin amyloidosis therapy, NTLA-2001, into what it hopes will be a pivotal study. By Conor Hale The life science venture capital firm Apple Tree Partners has brought three of its portfolio companies together under a single banner to pursue energy therapies for chronic bronchitis, cardiac arrhythmias and solid tumors. By Annie Burky Twenty percent of children have specialty health needs, but 39 million children in the U.S. live more than 80 miles from a pediatric subspecialist. Boston Children's Hospital teamed up with virtual specialist platform Summus Global earlier this year to expand virtual care for populations with complex healthcare needs. By Teresa Carey This week on "The Top Line," we chat about this year’s European Society for Medical Oncology meeting, where Merck presented a series of trial flops for Keytruda. We also discuss the lessons learned from the COVID-19 pandemic and how they are being applied to the monkeypox test EUA. By James Waldron Nordic Nanovector is shedding board members as the Norwegian biotech continues to seek out options for survival in the wake of discontinuing its lymphoma trial. By Andrea Park As Neuron23's drug development continues, Qiagen will get started on building a companion diagnostic that’ll be able to predict how responsive Parkinson’s patients might be to an LRRK2 inhibitor—making it the first companion diagnostic developed for the neurodegenerative disease. By Frank Diamond Employers face difficult challenges in the next few years. And with limited budgets, the challenge of making decisions that consider healthcare affordability and engagement is exponentially greater. Fierce podcasts Don't miss an episode | This week on "The Top Line," we chat about this year’s European Society for Medical Oncology meeting, where Merck presented a series of trial flops for Keytruda. We also discuss the lessons learned from the COVID-19 pandemic and how they are being applied to the monkeypox test EUA. |
|
|---|
|
| Wednesday, September 28, 2022 | 2pm ET / 11am PT Explore the top line items every SMB marketer should focus on when commercializing new-to-market products, including shifts in the way that HCPs interact with pharma companies post-pandemic, and more. Register now. 
|
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn AI eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent | | |
|
